Kelvin Open Science Publishers
Connect with Research Community

Review Article Volume 1 | Issue 2

KOS Journal of AIML, Data Science, and Robotics
https://kelvinpublishers.com/journals/aiml-data-science-robotics.php

The Role of Artificial Intelligence in the Early Detection of Alzheimer's Disease

Mohamed Atef Mohamed Moselhy Elasalouty*

2nd Year Medical Student, Saint Petersburg University, Cairo, Egypt

***Corresponding author:** Mohamed Atef Mohamed Moselhy Elasalouty, 2nd Year Medical Student, Saint Petersburg University, Cairo, Egypt

Received: September 18, 2025; **Accepted:** September 21, 2025; **Published:** September 23, 2025

Citation: Mohamed AMME. (2025) The Role of Artificial Intelligence in the Early Detection of Alzheimer's Disease. *KOS J AIML, Data Sci, Robot.* 1(2): 1-2.

1. Abstract

Alzheimer's disease (AD) is one of the most prevalent causes of dementia worldwide, with incidence rising alongside aging populations. Early detection is critical, as it enables timely intervention, slows progression, and improves quality of life. In recent years, artificial intelligence (AI) has demonstrated remarkable potential in identifying early signs of AD through neuroimaging, speech and language analysis, and predictive modeling. This review summarizes the current applications of AI in these domains, highlights the challenges limiting its integration into clinical practice, and discusses future perspectives for AI driven diagnostics.

2. Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, cognitive decline, and functional disability. It accounts for nearly 70% of dementia cases and affects more than 55 million individuals worldwide. Given the absence of curative treatments, early and accurate diagnosis is essential.

Traditional diagnostic approaches including magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers, and cognitive testing are informative but often invasive, costly, and insufficiently sensitive in preclinical stages.

Artificial intelligence, with its capacity to process large and complex datasets, uncover subtle patterns, and enhance diagnostic precision, is now emerging as a transformative tool in AD detection [1-3].

3. Pathophysiology and Current Diagnostics

AD pathology is driven by the accumulation of amyloid β plaques and tau neurofibrillary tangles, leading to progressive neuronal loss. Importantly, these changes begin years before clinical symptoms manifest, creating a valuable "window of opportunity" for early intervention.

Current diagnostic methods include:

Neuroimaging (MRI, PET): Detects structural and functional changes.

Biomarkers (CSF assays): Identifies amyloid and tau proteins.

Neurocognitive testing: Assesses memory, attention, and executive function.

Although valuable, these approaches remain limited for population wide screening and early detection [4].

4. Applications of AI in Early Detection

4.1. Neuroimaging

Convolutional neural networks (CNNs) have shown high sensitivity in identifying subtle anatomical changes on MRI and PET scans, achieving accuracy rates exceeding 95% in large scale studies. Hybrid AI models that integrate multiple imaging modalities further enhance predictive performance [1].

4.2. Speech and language analysis

Natural language processing (NLP) detects early linguistic markers of cognitive decline, including reductions in vocabulary richness, syntactic complexity, and rhythm. These "digital biomarkers" offer a non-invasive and accessible means of monitoring cognitive health [3].

4.3. Predictive modeling

Machine learning models that combine genetic, clinical, and imaging data can estimate individual risk with increasing precision. Multimodal algorithms integrating MRI, biomarkers, and cognitive data demonstrate robust predictive capacity, even when datasets are incomplete [2].

5. Challenges and Limitations

Data quality and diversity: AI models require large, standardized, and representative datasets [5].

Ethical considerations: Patient privacy, bias, and informed consent remain critical issues.

Clinical translation: Many AI tools show promise in research but lack validation in real world healthcare settings [6].

6. Future Perspectives

AI has the potential to make AD detection earlier, more accurate, and more accessible.

Recent advances include:

Blood based biomarkers: In 2025, the FDA approved a blood test measuring phosphorylated tau (p Tau217) and β amyloid 1-42, offering a less invasive alternative to CSF analysis and PET imaging [7].

Sleep EEG analysis: AI models applied to sleep electroencephalography (EEG) data predicted cognitive decline years before symptom onset with ~77% accuracy [8].

The future lies in integrating these innovations into scalable, cost effective diagnostic frameworks for widespread clinical use.

7. Conclusion

Artificial intelligence is reshaping the landscape of Alzheimer's disease diagnostics by detecting early pathological changes across imaging, speech, and multimodal datasets. While challenges remain particularly regarding data quality, ethics, and clinical adoption the rapid progress of AI driven methods is highly promising. For medical students and young researchers, this field represents a dynamic intersection of neuroscience, technology, and patient care, offering opportunities to contribute meaningfully to the fight against dementia.

8. References

1. Sharma S, Gupta S, Gupta D, et al. (2022) Hybrid AI-based model for detection of Alzheimer's disease. Diagnostics. 12(9): 2147.
2. Zhang Y, Wang J, Chen L, et al. (2025) Multimodal deep learning for Alzheimer's detection. arXiv preprint.
3. Fraser KC, Meltzer JA, Rudzicz F. (2020) Linguistic features identify Alzheimer's disease in narrative speech. J Alzheimers Dis. 77(3): 1005-1015.
4. Jack CR Jr, Bennett DA, Blennow K, et al. (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 14(4): 535-562.
5. Pellegrini L, Baecker D. (2023) Artificial intelligence for biomarker discovery in Alzheimer's disease. Alzheimers Dement. 19(5): 1960-1974.
6. Montagna S. (2025) Machine learning for dementia classification using multimodal biomarkers. Sci Rep. 15: 93513.
7. U.S. FDA. (2025) FDA clears first blood test used in diagnosing Alzheimer's disease.
8. Mass General Brigham. (2024) Brain waves during sleep predict cognitive impairment with AI.